Preventing mother-to-child transmission of HIV in Western Kenya: operational issues

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):344-9. doi: 10.1097/01.qai.0000160712.86580.ff.

Abstract

Objectives: To improve uptake in a program to prevent mother-to-child HIV transmission and describe lessons relevant for prevention of mother-to-child transmission programs in resource-poor settings.

Methods: Implementation of a pilot project that evaluates approaches to increase program uptake at health facility level at New Nyanza Provincial General Hospital, a public hospital in western Kenya, an area with high HIV prevalence. Client flow was revised to integrate counseling, HIV testing, and dispensing of single-dose nevirapine into routine antenatal services. The number of facilities providing PMCT services was expanded to increase district-wide coverage. Main outcome measures were uptake of counseling, HIV testing, nevirapine, and estimated program impact.

Results: Uptake of counseling and testing improved from 55 to 68% (P < 0.001), nevirapine uptake from 57% to 70% (P < 0.001), and estimated program impact from 15% to 23% (P = 0.03). Aggregate reports compare well with computer-entered data.

Conclusion: Addressing institutional factors can improve uptake, but expected program impact remains low for several reasons, including relatively low efficacy of the intervention and missed opportunities in the labor room.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Counseling
  • Developing Countries*
  • Female
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy
  • HIV Infections / prevention & control*
  • HIV Infections / transmission*
  • Hospitals, General
  • Hospitals, Public*
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Kenya
  • Nevirapine / therapeutic use*
  • Pilot Projects
  • Pregnancy
  • Pregnancy Complications, Infectious / prevention & control*
  • Program Evaluation*

Substances

  • Anti-HIV Agents
  • Nevirapine